Bioequivalence Evidence Boundary / 生物等效性证据边界

Definition

Bioequivalence evidence boundary is the distinction between showing sufficiently comparable systemic exposure to a reference medicine under a defined protocol and proving that two products are identical in composition, tissue effects, adverse effects, or every patient’s clinical experience.

Current Synthesis

VOL.151 presents bioequivalence as a practical bridge between full originator development and unsupported copying. Blood-concentration measures can show that a chemical generic and reference product behave comparably enough under specified conditions, while avoiding the claim that crystal form, excipients, manufacturing, release behavior, impurities, local exposure, or tolerability are therefore literally identical.

The boundary supports proportional confidence rather than reflexive distrust. Comparable exposure is meaningful evidence, especially for established small-molecule products, but its clinical sufficiency depends on therapeutic margin, dosage form, population, outcome severity, and monitoring. The episode’s “80%-125%” explanation is retained only as source shorthand: without the protocol and statistical definition, it must not be translated into arbitrary allowed variation in dose content or individual response.

Key Claims

• Bioequivalence compares defined pharmacokinetic behavior rather than every possible clinical property.
• Comparable systemic exposure is meaningful regulatory evidence and should not be dismissed as “no evidence.”
• Product sameness cannot be inferred across formulation, impurities, release behavior, tissue effects, tolerability, and all patients.
• The meaning of residual uncertainty grows as the therapeutic margin narrows or consequences become more severe.
• Numerical equivalence bounds require their statistical and protocol context to be interpreted correctly.

Evidence

• Evidentiary role: VOL.151大物是也·大白牛：仿制药和原研药药效一样吗？什么是“一致性评价”？到底哪些疾病可以选用仿制药？ describes human blood-concentration comparison as the standard bridge for many chemical generics.
• Non-identity boundary: VOL.151大物是也·大白牛：仿制药和原研药药效一样吗？什么是“一致性评价”？到底哪些疾病可以选用仿制药？ distinguishes pharmacokinetic similarity from identical tissue response, side effects, crystal form, excipients, synthesis, purity, and release behavior.
• Clinical interpretation: VOL.151大物是也·大白牛：仿制药和原研药药效一样吗？什么是“一致性评价”？到底哪些疾病可以选用仿制药？ links the practical weight of residual differences to therapeutic index, patient group, disease consequence, and treatment stability.

Counterevidence & Qualifications

The supplied source does not identify the governing jurisdiction, study design, pharmacokinetic endpoints, confidence-interval method, fasting or fed condition, replicate design, or special rules for narrow-therapeutic-index and highly variable drugs. It therefore cannot support a universal technical account of the 80%-125% criterion. Nor does the source establish that observed differences between products are clinically important in general. Bioequivalence requirements, product-specific guidances, and biosimilar comparability are not interchangeable, and patient-level treatment decisions remain product- and condition-specific.

What Changed

• Established a boundary that treats bioequivalence as meaningful comparability evidence without inflating it into literal identity.
• Explicitly qualified the episode’s simplified numerical range against missing statistical and protocol context.

Related Concepts

• Generic Drug Substitution Decision / 仿制药替换决策 - applies bioequivalence evidence within patient- and medicine-specific risk decisions.
• Generic Drug Trust Rebuilding / 仿制药再信任 - adds system-level quality credibility and professional explanation.
• Medical Risk Management - scales action to consequence, uncertainty, and monitoring capacity.
• Clinical Development Capability - broader capability for generating interpretable human efficacy and safety evidence.